United Bioscience (UBC) Scientific Policy Director Appointed to Medicare Coverage Advisory Committee (MCAC)
Health Care Industry Executive and Consultant Dr. Bryan R. Luce Will Help Guide Medicare Policy Over the Next Two Years
BETHESDA, MD (May 27, 2005) - United BioSource Corporation (UBC), a leading provider of comprehensive evidence-based drug evaluation services, today announced that Dr. Bryan R. Luce has been invited to serve as a member of the Medicare Coverage Advisory Committee (MCAC). Dr. Luce is the Scientific Policy Director and founder of The MEDTAP Institute, the scientific research arm of UBC.
"I am honored to contribute to this important group and help guide our nation's Medicare policy," said Dr. Luce. "As the emphasis on evidence-based medicine continues to grow, especially in light of the Medicare Modernization Act, the government is under greater pressure to make informed and supportable coverage decisions. UBC and The MEDTAP Institute have become industry leaders in exactly this sort of evaluation, so our expertise should be very useful to the Committee."
Dr. Bryan Luce has spent many years as a health care industry executive, and has served as a consultant to numerous government agencies as well as pharmaceutical and device firms worldwide. From 1995 to 2002, Dr. Luce was Chairman, President and CEO of MEDTAP. Previously, he held positions as the Director of Battelle's Centers for Public Health Research and Evaluation, Director of the Office of Research and Demonstrations at the Health Care Financing Administration, and Senior Analyst in the former Congressional Office of Technology Assessment.
Luce will serve on the MCAC for a period of two years beginning in the summer of 2005. The MCAC advises the Centers for Medicare and Medicaid Services (CMS) on whether specific medical items and services are reasonable and necessary under Medicare law. It performs this task through a careful review and discussion of specific clinical and scientific issues, and it does so in an open and public forum. MCAC members are valued for their background, education and expertise in a wide variety of scientific, clinical and other related fields.
About UBC
United BioSource Corporation (UBC) delivers evidence-based solutions to optimize the medical and commercial potential of pharmaceuticals, biotechnology, medical devices, and diagnostics. UBC is based in Bethesda, Maryland. For more information about UBC, visit www.unitedbiosource.com or call 240-644-0420.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
